Trisomy 21: Fifty years between medicine and science;Trisomie 21: 50 ans entre médecine et science

Medecine/Sciences

Volumn 26, Issue 3, 2010, Pages 267-272

  Turleau, Catherine ^a   Vekemans, Michel ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; CHROMOSOME 21; DOWN SYNDROME; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKER; GENETICS; HUMAN; MALE; MEIOSIS; MITOSIS; MOUSE; NONDISJUNCTION; REVIEW; RISK FACTOR; TELOMERE;

ANIMALS; CHROMOSOMES, HUMAN, PAIR 21; DOWN SYNDROME; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; MALE; MEIOSIS; MICE; MITOSIS; NONDISJUNCTION, GENETIC; RISK FACTORS; TELOMERE;

EID: 77951793467     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/2010263267     Document Type: Review

References (52)

1. Lejeune J, Gautier M, Turpin R. Study of somatic chromosomes from 9 mongoloid children. CR Hebd Seances Acad Sci 1959; 248: 1721-2.
2. Hassold T, Hunt P. To err (meiotically) is human: the genesis of human aneuploidy. Nat Rev Genet 2001; 2: 280-91.
3. Antonarakis SE. Parental origin of the extra chromosome in trisomy 21 as indicated by analysis of DNA polymorphisms. Down syndrome collaborative group. N Engl J Med 1991; 324: 872-6.
4. Savage AR, Petersen MB, Pettay D, et al. Elucidating the mechanisms of paternal non-disjunction of chromosome 21 in humans. Hum Mol Genet 1998; 7: 1221-7.
5. Lamb NE, Feingold E, Savage A, et al. Characterization of susceptible chiasma configurations that increase the risk for maternal nondisjunction of chromosome 21. Hum Mol Genet 1997; 6: 1391-9.
6. Warren AC, Chakravarti A, Wong C, et al. Evidence for reduced recombination on the nondisjoined chromosomes 21 in Down syndrome. Science 1987; 237: 652-4.
7. Lamb NE, Freeman SB, Savage-Austin A, et al. Susceptible chiasmate configurations of chromosome 21 predispose to non-disjunction in both maternal meiosis I and meiosis II. Nat Genet 1996; 14: 400-5.
8. Antonarakis SE, Avramopoulos D, Blouin JL, Talbot CC Jr, Schinzel AA. Mitotic errors in somatic cells cause trisomy 21 in about 4.5% of cases and are not associated with advanced maternal age. Nat Genet 1993; 3: 146-50.
9. Warburton D. Biological aging and the etiology of aneuploidy. Cytogenet Genome Res 2005; 111: 266-72.
10. Pellestor F, Anahory T, Hamamah S. Effect of maternal age on the frequency of cytogenetic abnormalities in human oocytes. Cytogenet Genome Res 2005; 111: 206-12.
11. Allen EG, Freeman SB, Druschel C, et al. Maternal age and risk for trisomy 21 assessed by the origin of chromosome nondisjunction: a report from the Atlanta and National Down Syndrome Projects. Hum Genet 2009; 125: 41-52.
12. Oliver TR, Feingold E, Yu K, et al. New insights into human nondisjunction of chromosome 21 in oocytes. PLoS Genet 2008; 4: e1000033.
13. Hodges RJ, Wallace EM. Testing for Down syndrome in the older woman: a risky business? Aust NZ J Obstet Gynaecol 2005; 45: 486-8.
14. Epstein CJ, Korenberg JR, Anneren G, et al. Protocols to establish genotype-phenotype correlations in Down syndrome. Am J Hum Genet 1991; 49: 207-35.
15. Gardiner K, Fortna A, Bechtel L, Davisson MT. Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene 2003; 318: 137-47.
16. Davisson MT, Schmidt C, Akeson EC. Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog Clin Biol Res 1990; 360: 263-80.
17. Sago H, Carlson EJ, Smith DJ, et al. Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc Natl Acad Sci USA 1998; 95: 6256-61.
18. Shinohara T, Tomizuka K, Miyabara S, et al. Mice containing a human chromosome 21 model behavioral impairment and cardiac anomalies of Down's syndrome. Hum Mol Genet 2001; 10: 1163-75.
19. Tan YH, Tischfield J, Ruddle FH. The linkage of genes for the human interferon-induced antiviral protein and indophenol oxidase-B traits to chromosome G-21. J Exp Med 1973; 137: 317-30.
20. Hattori M, Fujiyama A, Taylor TD, et al. The DNA sequence of human chromosome 21. Nature 2000; 405: 311-9.
21. Gardiner K, Costa AC. The proteins of human chromosome 21. Am J Med Genet C Semin Med Genet 2006; 142C: 196-205.
22. Dermitzakis ET, Reymond A, Lyle R, et al. Numerous potentially functional but non-genic conserved sequences on human chromosome 21. Nature 2002; 420: 578-82.
23. Kuhn DE, Nuovo GJ, Martin MM, et al. Human chromosome 21-derived miRNAs are overexpressed in down syndrome brains and hearts. Biochem Biophys Res Commun 2008; 370: 473-7.
24. Reymond A, Marigo V, Yaylaoglu MB, et al. Human chromosome 21 gene expression atlas in the mouse. Nature 2002; 420: 582-6.
25. Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat Rev Genet 2004; 5: 725-38.
26. Rachidi M, Lopes C. Mental retardation and associated neurological dysfunctions in Down syndrome: a consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways. Eur J Paediatr Neurol 2008; 12: 168-82.
27. Ait Yahya-Graison E, Aubert J, Dauphinot L, et al. Classification of human chromosome 21 geneexpression variations in Down syndrome: impact on disease phenotypes. Am J Hum Genet 2007; 81: 475-91.
28. Prandini P, Deutsch S, Lyle R, et al. Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. Am J Hum Genet 2007; 81: 252-63.
29. FitzPatrick DR. Transcriptional consequences of autosomal trisomy: primary gene dosage with complex downstream effects. Trends Genet 2005; 21: 249-53.
30. Mao R, Zielke CL, Zielke HR, Pevsner J. Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain. Genomics 2003; 81: 457-67.
31. Delabar JM, Theophile D, Rahmani Z, et al. Molecular mapping of twenty-four features of Down syndrome on chromosome 21. Eur J Hum Genet 1993; 1: 114-24.
32. Korenberg Jr. Molecular mapping of the Down syndrome phenotype. Prog Clin Biol Res 1990; 360: 105-15.
33. Rahmani Z, Blouin JL, Creau-Goldberg N, et al. Down syndrome critical region around D21S55 on proximal 21q22.3. Am J Med Genet 1990; 7 (suppl): 98-103.
34. Ronan A, Fagan K, Christie L, et al. Familial 4.3 Mb duplication of 21q22 sheds new light on the Down syndrome critical region. J Med Genet 2007; 44: 448-51.
35. Korenberg JR, Chen XN, Schipper R, et al. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc Natl Acad Sci USA 1994; 91: 4997-5001.
36. Shapiro BL. The Down syndrome critical region. J Neural Transm 1999; 57 (suppl): 41-60.
37. Olson LE, Richtsmeier JT, Leszl J, Reeves RH. A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science 2004; 306: 687-90.
38. Olson LE, Roper RJ, Sengstaken CL, et al. Trisomy for the Down syndrome "critical region" is necessary but not sufficient for brain phenotypes of trisomic mice. Hum Mol Genet 2007; 16: 774-82.
39. Lyle R, Gehrig C, Neergaard-Henrichsen C, Deutsch S, Antonarakis SE: Gene expression from the aneuploid chromosome in a trisomy mouse model of down syndrome. Genome Res 2004; 14: 1268-74.
40. Korbel JO, Tirosh-Wagner T, Urban AE, et al. The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc Natl Acad Sci USA 2009; 106: 12031-6.
41. Reeves RH, Baxter LL, Richtsmeier JT. Too much of a good thing: mechanisms of gene action in Down syndrome. Trends Genet 2001; 17: 83-8.
42. Crispino JD. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. Pediatr Blood Cancer 2005; 44: 40-4.
43. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol 2001; 2: 429-36.
44. Guidi S, Bonasoni P, Ceccarelli C, et al. Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Pathol 2008; 18: 180-97.
45. Lorenzi HA, Reeves RH. Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Brain Res 2006; 1104: 153-9.
46. Arron JR, Winslow MM, Polleri A, et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 2006; 441: 595-600.
47. Canzonetta C, Mulligan C, Deutsch S, et al. DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. Am J Hum Genet 2008; 83: 388-400.
48. Fernandez F, Morishita W, Zuniga E, et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 2007; 10: 411-3.
49. Costa AC, Scott-McKean JJ, Stasko MR. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 2008; 33: 1624-32.
50. Guedj F, Sebrie C, Rivals I, et al. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS One 2009; 4: e4606.
51. Turleau C, Vekemans M. Nouvelles données en géné tique chromosomique. Med Sci (Paris) 2005; 21: 940-6.
52. Terret ME, Wassmann K. Le point faible méiotique: la première division. Med Sci (Paris) 2008; 24: 197-203.